Temat: "Receptor, ErbB-2" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Autorzy:: Kim YN; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
Chung YS; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
Park E; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Lee ST; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Lee JY; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Apr 05; Vol. 14 (1), pp. 7992. Date of Electronic Publication: 2024 Apr 05.
Typ publikacji:: Journal Article
MeSH Terms:: Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Receptor, ErbB-2*/metabolism
Female ; Humans ; Mutation ; Mutation Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.
Autorzy:: Pang J; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Ding N; Department of Clinical Laboratory, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yin N; Department of Operating Room, First People's Hospital of Changde, Changde, China.
Xiao Z; Department of Breast Surgery, Xiangya Hospital, Central South University, 87# Xiangya Road, Changsha, 410008, Hunan, China. .; Clinical Research Center for Breast Cancer in Hunan Province, Changsha, China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Mar 19; Vol. 14 (1), pp. 6578. Date of Electronic Publication: 2024 Mar 19.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Humans ; Female ; Trastuzumab/therapeutic use ; Prognosis ; Receptor, ErbB-2 ; Inflammation/drug therapy ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples.
Autorzy:: Antos A; SDS Optic, EcoTech Complex, Block A, Głęboka 39, 20-612, Lublin, Poland.
Topolska-Woś A; SDS Optic, EcoTech Complex, Block A, Głęboka 39, 20-612, Lublin, Poland.
Woś M; SDS Optic, EcoTech Complex, Block A, Głęboka 39, 20-612, Lublin, Poland.
Mitura A; SDS Optic, EcoTech Complex, Block A, Głęboka 39, 20-612, Lublin, Poland.
Sarzyńska P; SDS Optic, EcoTech Complex, Block A, Głęboka 39, 20-612, Lublin, Poland.
Lipiński T; Lukasiewicz Research Network - PORT Polish Center for Technology Development, Stabłowicka 147, 54-066, Wrocław, Poland.
Kurylcio A; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13, 20-080, Lublin, Poland.
Ziółkowski P; Department of Pathomorphology, Wrocław Medical University, Marcinkowskiego 1, 50-368, Wrocław, Poland.
Świtalska M; Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wrocław, Poland.
Tkaczuk-Włach J; Chair of Obstetrics and Gynecology, Faculty of Health Sciences, Medical University of Lublin, Staszica 4/6, 20-081, Lublin, Poland.
Gamian A; Laboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wrocław, Poland.
Polkowski WP; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13, 20-080, Lublin, Poland.
Staniszewska M; SDS Optic, EcoTech Complex, Block A, Głęboka 39, 20-612, Lublin, Poland. .; Faculty of Medicine, The John Paul II Catholic University of Lublin, Konstantynów 1J, 20-708, Lublin, Poland. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 17; Vol. 14 (1), pp. 3978. Date of Electronic Publication: 2024 Feb 17.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Monoclonal*/therapeutic use
Breast Neoplasms*/metabolism
Humans ; Female ; Receptor, ErbB-2 ; Enzyme-Linked Immunosorbent Assay/methods ; Cells, Cultured ; Biomarkers, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Comparative analysis of breast cancer characteristics in young premenopausal and postmenopausal women in Ghana.
Autorzy:: Bosompem K; Directorate of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Yorke J; Department of Surgery, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Buckman TA; Department of Medical Laboratory Science, KAAF University College, Buduburam, Ghana.
Brenu SG; Directorate of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Nyantakyi M; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Aitpillah FS; Directorate of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana.; Department of Surgery, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Kyei I; Department of Surgery, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Adinku MO; Directorate of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Yorke DA; Directorate of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Obirikorang C; Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Acheampong E; Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. .; Leicester Cancer Research Centre, Department of Genetic and Genome Biology, University of Leicester, Leicester, LE1 7RH, UK. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 01; Vol. 14 (1), pp. 2704. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/diagnosis
Breast Neoplasms*/epidemiology
Breast Neoplasms*/therapy
Triple Negative Breast Neoplasms*/pathology
Humans ; Female ; Postmenopause ; Ghana/epidemiology ; Cross-Sectional Studies ; Prospective Studies ; Receptor, ErbB-2/analysis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: A gene expression-based classifier for HER2-low breast cancer.
Autorzy:: Di Cosimo S; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Pizzamiglio S; Bioinformatics and Biostatistics Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. .
Ciniselli CM; Bioinformatics and Biostatistics Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Duroni V; Bioinformatics and Biostatistics Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Cappelletti V; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
De Cecco L; Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
De Marco C; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Silvestri M; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
De Santis MC; Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Vingiani A; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Paolini B; Department of Pathology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Orlandi R; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Iorio MV; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Pruneri G; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Verderio P; Bioinformatics and Biostatistics Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 01; Vol. 14 (1), pp. 2628. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/genetics
Humans ; Female ; Receptor, ErbB-2/metabolism ; Genes, erbB-2 ; Immunohistochemistry ; Gene Expression ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer.
Autorzy:: Park J; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Department of Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Kang SK; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Kwon WS; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Jeong I; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Kim TS; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Yu SY; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Cho SW; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Chung HC; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Department of Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.; Yonsei Cancer Center, Yonsei University Health System, Seoul, 03722, Republic of Korea.; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Rha SY; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. .; Department of Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. .; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. .; Yonsei Cancer Center, Yonsei University Health System, Seoul, 03722, Republic of Korea. .; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Dec 19; Vol. 13 (1), pp. 22648. Date of Electronic Publication: 2023 Dec 19.
Typ publikacji:: Journal Article
MeSH Terms:: Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/genetics
Stomach Neoplasms*/pathology
Immunoconjugates*/pharmacology
Humans ; Receptor, ErbB-2/metabolism ; Antibodies, Monoclonal, Humanized/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Cell Proliferation ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity.
Autorzy:: Ng CW; Department of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Wong KK; Department of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Dec 05; Vol. 13 (1), pp. 21454. Date of Electronic Publication: 2023 Dec 05.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/genetics
Deep Learning*
Humans ; Female ; Receptor, ErbB-2/genetics ; Biomarkers, Tumor/genetics ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer.
Autorzy:: Shikata S; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Murata T; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. .
Yoshida M; Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hashiguchi H; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yoshii Y; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ogawa A; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Watase C; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shiino S; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Sugino H; Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Jimbo K; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Maeshima A; Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Iwamoto E; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takayama S; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Suto A; Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Nov 11; Vol. 13 (1), pp. 19669. Date of Electronic Publication: 2023 Nov 11.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/pathology
Humans ; Female ; Prognosis ; Ki-67 Antigen ; Retrospective Studies ; Neoplasm Recurrence, Local ; Receptor, ErbB-2/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype.
Autorzy:: Orrù S; Department of Pathology, 'A. Businco' Oncologic Hospital, ARNA S Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Pascariello E; Department of Pathology, 'A. Businco' Oncologic Hospital, ARNA S Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Pes B; Dipartimento di Matematica e Informatica, University of Cagliari, Palazzo delle Scienze, Via Ospedale 72, 09124, Cagliari, Italy.
Rallo V; Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, CNR, Cittadella Universitaria di Cagliari, 09042, Monserrato, Cagliari, Italy.
Barbara R; Department of Radiotherapy, 'A. Businco' Oncologic Hospital, ARNAS Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Muntoni M; Department of Pathology, 'A. Businco' Oncologic Hospital, ARNA S Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Notari F; Department of Pathology, 'A. Businco' Oncologic Hospital, ARNA S Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Fancello G; Breast Surgery Department, 'A. Businco' Oncologic Hospital, ARNAS Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Mocci C; Department of Pathology, 'A. Businco' Oncologic Hospital, ARNA S Brotzu, Via Edward Jenner 1, 09121, Cagliari, Italy.
Muroni MR; Department of Medicine, Surgery and Pharmacy, University of Sassari, Via P. Manzella 4, 07100, Sassari, Italy.
Cossu-Rocca P; Department of Medicine, Surgery and Pharmacy, University of Sassari, Via P. Manzella 4, 07100, Sassari, Italy.; Department of Diagnostic Services, 'Giovanni Paolo II' Hospital, ASSL Olbia-ATS Sardegna, Via Bazzoni-Sircana, 07026, Olbia, Italy.
Angius A; Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, CNR, Cittadella Universitaria di Cagliari, 09042, Monserrato, Cagliari, Italy. .
De Miglio MR; Department of Medicine, Surgery and Pharmacy, University of Sassari, Via P. Manzella 4, 07100, Sassari, Italy. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Aug 08; Vol. 13 (1), pp. 12869. Date of Electronic Publication: 2023 Aug 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Humans ; Female ; Neoadjuvant Therapy ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use ; Lymphocytes, Tumor-Infiltrating ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.
Autorzy:: Ye P; Department of Anatomy and Histology, School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Li F; Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, People's Republic of China.
Wei Y; Department of Physiology, School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Zhang Y; School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Cui J; School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Dai R; School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Chen H; School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Xie J; Department of Pathology and Clinical Laboratory, Sichuan Provincial Fourth People's Hospital, Chengdu, Sichuan Province, People's Republic of China. .
Cai P; Department of Anatomy and Histology, School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2022 Jul 28; Vol. 12 (1), pp. 12894. Date of Electronic Publication: 2022 Jul 28.
Typ publikacji:: Journal Article
MeSH Terms:: Colorectal Neoplasms*/pathology
Receptor, ErbB-2*/metabolism
Biomarkers, Tumor/genetics ; ErbB Receptors/metabolism ; Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis ; Receptor, ErbB-3 ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Evaluation of an I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.
Autorzy:: Feng Y; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Meshaw R; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
McDougald D; Department of Radiology, Duke University Medical Center, Durham, NC, USA.; Cereius Inc, Durham, NC, USA.
Zhou Z; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Zhao XG; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Jannetti SA; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Reiman RE; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Pippen E; Cereius Inc, Durham, NC, USA.
Marjoram R; Cereius Inc, Durham, NC, USA.
Schaal JL; Cereius Inc, Durham, NC, USA.
Vaidyanathan G; Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Zalutsky MR; Department of Radiology, Duke University Medical Center, Durham, NC, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2022 Feb 22; Vol. 12 (1), pp. 3020. Date of Electronic Publication: 2022 Feb 22.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms/*drug therapy
Breast Neoplasms/*genetics
Gastrointestinal Neoplasms/*drug therapy
Gastrointestinal Neoplasms/*genetics
Gene Expression/*genetics
Immunoglobulin Fragments/*therapeutic use
Iodine Radioisotopes/*pharmacology
Iodine Radioisotopes/*therapeutic use
Ovarian Neoplasms/*drug therapy
Ovarian Neoplasms/*genetics
Radiopharmaceuticals/*pharmacology
Radiopharmaceuticals/*therapeutic use
Receptor, ErbB-2/*genetics
Receptor, ErbB-2/*immunology
Single-Domain Antibodies/*pharmacology
Single-Domain Antibodies/*therapeutic use
Animals ; Disease Models, Animal ; Female ; Humans ; Receptor, ErbB-2/metabolism ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study.
Autorzy:: Abbasvandi F; Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, P.O. Box 1517964311, Tehran, Iran.
Bayat M; Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akbari A; Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shojaeian F; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zandi A; School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Rahmani J; Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hashemi MO; Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akbari ME; Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Oct 04; Vol. 13 (1), pp. 16719. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms*/pathology
Humans ; Female ; Retrospective Studies ; Receptor, ErbB-2 ; Prognosis ; Survival Rate ; Iran

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells.
Autorzy:: Hassan G; Department of Biotechnology and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 3.1.1 Tsushima-Naka, Kita, Okayama, 700-8530, Japan.; Department of Genomic Oncology and Oral Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, 734-8553, Japan.
Zahra MH; Department of Biotechnology and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 3.1.1 Tsushima-Naka, Kita, Okayama, 700-8530, Japan.
Seno A; Department of Biotechnology and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 3.1.1 Tsushima-Naka, Kita, Okayama, 700-8530, Japan.; The Laboratory of Natural Food and Medicine, Co., Ltd., Okayama, 700-8530, Japan.
Seno M; Department of Biotechnology and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 3.1.1 Tsushima-Naka, Kita, Okayama, 700-8530, Japan. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2022 Feb 17; Vol. 12 (1), pp. 2711. Date of Electronic Publication: 2022 Feb 17.
Typ publikacji:: Journal Article
MeSH Terms:: Induced Pluripotent Stem Cells/*metabolism
Neoplastic Stem Cells/*metabolism
Receptor, ErbB-2/*metabolism
Receptor, ErbB-3/*metabolism
Acrylamides/pharmacology ; Adenine/analogs & derivatives ; Adenine/pharmacology ; Carcinoma, Pancreatic Ductal/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Cell Self Renewal/drug effects ; Culture Media, Conditioned ; Gene Expression Regulation, Neoplastic ; Humans ; Lapatinib/pharmacology ; MAP Kinase Signaling System ; Pancreatic Neoplasms/metabolism ; Protein Kinase Inhibitors/pharmacology ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-3/antagonists & inhibitors ; Receptor, ErbB-3/genetics ; Signal Transduction ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
Autorzy:: Maeda S; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan. .
Sakai K; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.; Veterinary Medical Center, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Kaji K; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Iio A; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Nakazawa M; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Motegi T; Veterinary Medical Center, The University of Tokyo, Tokyo, Japan.
Yonezawa T; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Momoi Y; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2022 Jan 13; Vol. 12 (1), pp. 4. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji:: Clinical Trial, Veterinary; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Lapatinib/*therapeutic use
Piroxicam/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Receptor, ErbB-2/*genetics
Urinary Bladder Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/therapeutic use ; Dog Diseases/drug therapy ; Dogs ; Drug Therapy, Combination/adverse effects ; Female ; Gene Expression Regulation, Neoplastic ; Lapatinib/adverse effects ; Male ; Muscles ; Receptor, ErbB-2/antagonists & inhibitors ; Treatment Outcome ; Urinary Bladder Neoplasms/veterinary

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer.
Autorzy:: Chung WP; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Huang WL; Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.; Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Liao WA; Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hung CH; Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Chiang CW; Institute of Molecular Medicine, College of Medicine and Center for Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan.
Cheung CHA; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .
Su WC; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .; Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2022 Jan 07; Vol. 12 (1), pp. 241. Date of Electronic Publication: 2022 Jan 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms/*drug therapy
Fingolimod Hydrochloride/*administration & dosage
Receptor, ErbB-2/*genetics
Animals ; Apoptosis/drug effects ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Breast Neoplasms/physiopathology ; Cell Line, Tumor ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Drug Resistance, Neoplasm ; Female ; Humans ; Mice ; Mice, Inbred BALB C ; Receptor, ErbB-2/metabolism ; Trastuzumab/administration & dosage ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images.
Autorzy:: Xue T; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Chang H; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Ren M; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Wang H; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Yang Y; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Wang B; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
Lv L; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
Tang L; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
Fu C; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
Fang Q; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
He C; Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
Zhu X; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China.
Zhou X; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China. .
Bai Q; Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College Fudan University, Shanghai, China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Jun 16; Vol. 13 (1), pp. 9746. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Deep Learning*
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Humans ; Female ; In Situ Hybridization, Fluorescence/methods ; Gene Amplification ; Artificial Intelligence ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Biomarkers, Tumor/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.
Autorzy:: Bhan A; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. .
Ansari K; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.; Celcuity LLC, Minneapolis, MN, 55446, USA.
Chen MY; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
Jandial R; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Oct 15; Vol. 11 (1), pp. 16866. Date of Electronic Publication: 2021 Oct 15.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Retracted Publication
MeSH Terms:: Brain Neoplasms/*drug therapy
Breast Neoplasms/*drug therapy
Induced Pluripotent Stem Cells/*drug effects
Lapatinib/*pharmacology
Neoplasm Metastasis/*pathology
Receptor, ErbB-2/*drug effects
Animals ; Antineoplastic Agents/pharmacology ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Drug Carriers/pharmacology ; Humans ; Induced Pluripotent Stem Cells/cytology ; Mice, Inbred NOD ; Mice, SCID ; Quinazolines/pharmacology ; Receptor, ErbB-2/metabolism ; Mice

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Clinicopathological characteristics of HER2-low breast cancer: a retrospective study.
Autorzy:: Yang M; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Sun J; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Liu L; Department of Nursing, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.; Department of Nursing, Shenzhen Hospital, Southern Medical University, Shenzhen, 518100, Guangdong, China.
Kong X; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Lin D; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Zhou H; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Gao J; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. gao_.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Jul 31; Vol. 13 (1), pp. 12382. Date of Electronic Publication: 2023 Jul 31.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms*/pathology
Humans ; Female ; Retrospective Studies ; Receptor, ErbB-2/metabolism ; Prognosis ; Receptors, Progesterone/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients.
Autorzy:: Albarakati N; Department of Blood and Cancer Research, King Abdullah International Medical Research Center, Jeddah, Kingdom of Saudi Arabia. .; King Saud Bin Abdulaziz University for Health Sciences, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia. .
Al-Ghamdi H; Department of Blood and Cancer Research, King Abdullah International Medical Research Center, Jeddah, Kingdom of Saudi Arabia.; King Saud Bin Abdulaziz University for Health Sciences, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia.
Al-Sowayan B; Department of Blood and Cancer Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; King Saud Bin Abdulaziz University for Health Sciences, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia.
Alshareeda A; Department of Blood and Cancer Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; King Saud Bin Abdulaziz University for Health Sciences, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Jul 20; Vol. 13 (1), pp. 11738. Date of Electronic Publication: 2023 Jul 20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Urinary Bladder Neoplasms*/genetics
Breast Neoplasms*
Humans ; Female ; Prognosis ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptor, ErbB-2/metabolism ; BRCA1 Protein/genetics ; Homologous Recombination ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; DNA-Binding Proteins/genetics ; Cell Cycle Proteins/genetics ; Tumor Suppressor Proteins/genetics ; Ubiquitin-Protein Ligases/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Predictive biological factors for late survival in patients with HER2-positive breast cancer.
Autorzy:: Kang YJ; Department of Surgery, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.
Oh SJ; Department of Surgery, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.
Bae SY; Department of Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Kim EK; Department of Surgery, Seoul National University College of Medicine, Breast Care Center, Seoul National University Bundang Hospital, Seoul, Republic of Korea.
Lee YJ; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Park EH; Department of Surgery, Dong-A University College of Medicine, Busan, South Korea.
Jeong J; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Park HK; Department of Surgery Breast Cancer Center, Gil Medical Center of Gachon University, Incheon, Republic of Korea.
Suh YJ; Division of Breast and Thyroid Surgical Oncology, Department of Surgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea.
Kim YS; Department of Surgery, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, 271, Cheonbo-ro, Uijeongbu-si, Gyeonggi-do, 11765, Republic of Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Jul 07; Vol. 13 (1), pp. 11008. Date of Electronic Publication: 2023 Jul 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms*/pathology
Female ; Humans ; Biomarkers, Tumor ; Lymph Nodes/pathology ; Prognosis ; Receptor, ErbB-2/genetics ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Receptor, ErbB-2"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Publikacja

Język